Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Natural Killer/T-cell Lymphoma × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 1562 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1534 Lymphoma, Non-Hodgkin 1074 Leukemia, Lymphocytic, Chronic, B-Cell 1001 Lymphoma, Follicular 945 Lymphoma, Large B-Cell, Diffuse 937 Hodgkin Disease 820 Leukemia 797 Lymphoma, Mantle-Cell 660 Leukemia, Myeloid, Acute 574 Burkitt Lymphoma 536 Multiple Myeloma 504 Lymphoma, B-Cell, Marginal Zone 478 Myelodysplastic Syndromes 451 Recurrence 398 Lymphoma, B-Cell 359 Lymphoma, Large-Cell, Immunoblastic 296 Lymphoma, T-Cell, Cutaneous 294 Waldenstrom Macroglobulinemia 290 Mycosis Fungoides 247 Neoplasms 231 Myeloproliferative Disorders 223 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 217 Neoplasms, Plasma Cell 213 Sezary Syndrome 208 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 195 Lymphoma, Large-Cell, Anaplastic 191 Leukemia, Myeloid, Accelerated Phase 186 Blast Crisis 182 Lymphoma, T-Cell, Peripheral 179

Interventions

isatuximab 1 cemiplimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04763616 2021-09-24

ICING

Samsung Medical Center

Phase 2 Recruiting

Natural Killer/T-cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡